CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

Binghe Xu; Ying Fan

doi:10.1016/S1470-2045(20)30757-9

CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?

Binghe Xu
, Ying Fan

医学部

Chinese Academy of Medical Sciences

科研成果: 期刊稿件 › 评论/辩论

13 引用（Scopus）

源语言	英语
页（从-至）	159-160
页数	2
期刊	The Lancet Oncology
卷	22
期	2
DOI	https://doi.org/10.1016/S1470-2045(20)30757-9
出版状态	已出版 - 2月 2021

联合国可持续发展目标

此成果有助于实现下列可持续发展目标：

可持续发展目标 3 良好健康与福祉

访问文件

10.1016/S1470-2045(20)30757-9

其它文件与链接

链接到 Scopus 的出版物

引用此

@article{dc2e7b23f32f4ad58650639822e3201d,

title = "CDK4/6 inhibition in early-stage breast cancer: how far is it from becoming standard of care?",

author = "Binghe Xu and Ying Fan",

year = "2021",

month = feb,

doi = "10.1016/S1470-2045(20)30757-9",

language = "英语",

volume = "22",

pages = "159--160",

journal = "The Lancet Oncology",

issn = "1470-2045",

publisher = "Elsevier Ltd",

number = "2",

}

TY - JOUR

T1 - CDK4/6 inhibition in early-stage breast cancer

T2 - how far is it from becoming standard of care?

AU - Xu, Binghe

AU - Fan, Ying

PY - 2021/2

Y1 - 2021/2

UR - https://www.scopus.com/pages/publications/85099935945

U2 - 10.1016/S1470-2045(20)30757-9

DO - 10.1016/S1470-2045(20)30757-9

M3 - 评论/辩论

C2 - 33460573

AN - SCOPUS:85099935945

SN - 1470-2045

VL - 22

SP - 159

EP - 160

JO - The Lancet Oncology

JF - The Lancet Oncology

IS - 2

ER -